{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:28:09Z","timestamp":1788413289773,"version":"build-2803163510"},"reference-count":247,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40263-025-01246-9","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T18:29:23Z","timestamp":1769279363000},"page":"305-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0351-2226","authenticated-orcid":false,"given":"Kylie","family":"McConville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"1246_CR1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200253","author":"EL Graham","year":"2024","unstructured":"Graham EL, Bove R, Costello K, Crayton H, Jacobs DA, Shah S, et al. Practical considerations for managing pregnancy in patients with multiple sclerosis. Neurol Clin Pract. 2024. https:\/\/doi.org\/10.1212\/CPJ.0000000000200253.","journal-title":"Neurol Clin Pract."},{"key":"1246_CR2","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler J. 2020;26:1816\u201321. https:\/\/doi.org\/10.1177\/1352458520970841.","journal-title":"Mult Scler J"},{"issue":"4","key":"1246_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210213","volume":"104","author":"KM Krysko","year":"2025","unstructured":"Krysko KM, Waltz M, Chitnis T, Weinstock-Guttman B, Aaen GS, Belman A, et al. Study of the association between menarche and disease course in pediatric multiple sclerosis. Neurology. 2025;104(4):e210213. https:\/\/doi.org\/10.1212\/WNL.0000000000210213.","journal-title":"Neurology"},{"key":"1246_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.5603\/PJNNS.A2020.0069","volume":"54","author":"W Brola","year":"2020","unstructured":"Brola W, Steinborn B. Pediatric multiple sclerosis \u2013 current status of epidemiology, diagnosis and treatment. Neurol Neurochir Pol. 2020;54:508\u201317. https:\/\/doi.org\/10.5603\/PJNNS.A2020.0069.","journal-title":"Neurol Neurochir Pol"},{"issue":"4","key":"1246_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0387-7604(03)00035-4","volume":"25","author":"N Gadoth","year":"2003","unstructured":"Gadoth N. Multiple sclerosis in children. Brain Dev. 2003;25(4):229\u201332. https:\/\/doi.org\/10.1016\/S0387-7604(03)00035-4.","journal-title":"Brain Dev"},{"issue":"1","key":"1246_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/S12883-019-1473-5","volume":"19","author":"A Azimi","year":"2019","unstructured":"Azimi A, Hanaei S, Sahraian MA, Mohammadifar M, Ramagopalan SV, Ghajarzadeh M. Age at menarche and risk of multiple sclerosis (MS): a systematic review and meta-analysis. BMC Neurol. 2019;19(1):286. https:\/\/doi.org\/10.1186\/S12883-019-1473-5.","journal-title":"BMC Neurol"},{"issue":"2","key":"1246_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/SCLEROSIS2020007","volume":"2","author":"A Mavridi","year":"2024","unstructured":"Mavridi A, Bompou ME, Redmond A, Archontakis-Barakakis P, Vavougios GD, Mitsikostas DD, et al. Current and emerging treatment options in pediatric onset multiple sclerosis. Sclerosis. 2024;2(2):88\u2013107. https:\/\/doi.org\/10.3390\/SCLEROSIS2020007.","journal-title":"Sclerosis"},{"key":"1246_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002880","volume":"87","author":"E Wassmer","year":"2016","unstructured":"Wassmer E, Chitnis T, Pohl D, Amato MP, Banwell B, Ghezzi A, et al. International pediatric MS study group global members symposium report. Neurology. 2016;87:S110. https:\/\/doi.org\/10.1212\/WNL.0000000000002880.","journal-title":"Neurology"},{"key":"1246_CR9","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1056\/NEJMOA1800149","volume":"379","author":"T Chitnis","year":"2018","unstructured":"Chitnis T, Arnold DL, Banwell B, Br\u00fcck W, Ghezzi A, Giovannoni G, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379:1017\u201327. https:\/\/doi.org\/10.1056\/NEJMOA1800149.","journal-title":"N Engl J Med"},{"key":"1246_CR10","unstructured":"FDA. Highlights of prescribing information - fingolimod. [cited 2025 Sep]; www.fda.gov\/medwatch. Accessed 14 Sep 2025."},{"key":"1246_CR11","unstructured":"Teriflunomide Accord | European Medicines Agency (EMA) [Internet]. [cited 2025 May 3]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/teriflunomide-accord. Accessed 3 May 2025."},{"key":"1246_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S1474-4422(21)00364-1","volume":"20","author":"T Chitnis","year":"2021","unstructured":"Chitnis T, Banwell B, Kappos L, Arnold DL, G\u00fcc\u00fcyener K, Deiva K, et al. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021;20:1001\u201311. https:\/\/doi.org\/10.1016\/S1474-4422(21)00364-1.","journal-title":"Lancet Neurol"},{"key":"1246_CR13","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1177\/1352458520932798","volume":"27","author":"A Ghezzi","year":"2021","unstructured":"Ghezzi A, Banwell B, Bar-Or A, Chitnis T, Dale RC, Gorman M, et al. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: practical considerations. Mult Scler J. 2021;27:1814\u201322. https:\/\/doi.org\/10.1177\/1352458520932798.","journal-title":"Mult Scler J"},{"key":"1246_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ANA.25737","volume":"88","author":"KM Krysko","year":"2020","unstructured":"Krysko KM, Graves JS, Rensel M, Weinstock-Guttman B, Rutatangwa A, Aaen G, et al. Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. Ann Neurol. 2020;88:42\u201355. https:\/\/doi.org\/10.1002\/ANA.25737.","journal-title":"Ann Neurol"},{"issue":"2","key":"1246_CR15","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/S00415-015-7979-X","volume":"263","author":"J Salzer","year":"2016","unstructured":"Salzer J, Lycke J, Wickstr\u00f6m R, Naver H, Piehl F, Svenningsson A. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol. 2016;263(2):322\u20136. https:\/\/doi.org\/10.1007\/S00415-015-7979-X.","journal-title":"J Neurol"},{"key":"1246_CR16","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.1007\/S00415-024-12610-Y","volume":"271","author":"A Carotenuto","year":"2024","unstructured":"Carotenuto A, Di Monaco C, Papetti L, Borriello G, Signoriello E, Masciulli C, et al. Pediatric-onset multiple sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod. J Neurol. 2024;271:6773\u201381. https:\/\/doi.org\/10.1007\/S00415-024-12610-Y.","journal-title":"J Neurol"},{"key":"1246_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1001\/JAMANEUROL.2023.5566","volume":"81","author":"N Benallegue","year":"2024","unstructured":"Benallegue N, Rollot F, Wiertlewski S, Casey R, Debouverie M, Kerbrat A, et al. Highly effective therapies as first-line treatment for pediatric-onset multiple sclerosis. JAMA Neurol. 2024;81:273\u201382. https:\/\/doi.org\/10.1001\/JAMANEUROL.2023.5566.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1246_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/13625187.2024.2434843","volume":"30","author":"GS Merki-Feld","year":"2025","unstructured":"Merki-Feld GS, Bove R, Haddad LB, Hellwig K, Hillert J, Houtchens M, et al. Family planning and contraception in people with multiple sclerosis: perspectives for obstetricians, gynaecologists, and other health care professionals involved in reproductive planning. Eur J Contracept Reprod Health Care. 2025;30(2):59\u201373. https:\/\/doi.org\/10.1080\/13625187.2024.2434843.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"1246_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102881","author":"JD Santoro","year":"2021","unstructured":"Santoro JD, Hurtubise B, Rosario JD, Pagarkar D, Wiegand SE, Su E, et al. Underutilization of contraception in young females with demyelinating disorders. Mult Scler Relat Disord. 2021. https:\/\/doi.org\/10.1016\/j.msard.2021.102881.","journal-title":"Mult Scler Relat Disord"},{"key":"1246_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/J.NEUROL.2013.09.010","volume":"170","author":"E Bodiguel","year":"2014","unstructured":"Bodiguel E, Bensa C, Brassat D, Laplaud D, Le Page E, Ouallet JC, et al. Multiple sclerosis and pregnancy. Rev Neurol. 2014;170:247\u201365. https:\/\/doi.org\/10.1016\/J.NEUROL.2013.09.010.","journal-title":"Rev Neurol"},{"key":"1246_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000338847","volume":"68","author":"K Keyhanian","year":"2012","unstructured":"Keyhanian K, Davoudi V, Etemadifar M, Amin M. Better prognosis of multiple sclerosis in patients who experienced a full-term pregnancy. Eur Neurol. 2012;68:150\u20135. https:\/\/doi.org\/10.1159\/000338847.","journal-title":"Eur Neurol"},{"issue":"3","key":"1246_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/JAMANEUROL.2019.4173","volume":"77","author":"KM Krysko","year":"2020","unstructured":"Krysko KM, Rutatangwa A, Graves J, Lazar A, Waubant E. Association between breastfeeding and postpartum multiple sclerosis relapses: a systematic review and meta-analysis. JAMA Neurol. 2020;77(3):327\u201338. https:\/\/doi.org\/10.1001\/JAMANEUROL.2019.4173.","journal-title":"JAMA Neurol"},{"key":"1246_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000959","author":"A Anderson","year":"2021","unstructured":"Anderson A, Krysko KM, Rutatangwa A, Krishnakumar T, Chen C, Rowles W, et al. Clinical and radiologic disease activity in pregnancy and postpartum in MS. Neurol Neuroimmunol Neuroinflamm. 2021. https:\/\/doi.org\/10.1212\/NXI.0000000000000959.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1246_CR24","doi-asserted-by":"publisher","first-page":"105738","DOI":"10.1016\/J.MSARD.2024.105738","volume":"88","author":"R Bove","year":"2024","unstructured":"Bove R, Applebee A, Bawden K, Fine C, Shah A, Avila RL, et al. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis. Mult Scler Relat Disord. 2024;88:105738. https:\/\/doi.org\/10.1016\/J.MSARD.2024.105738.","journal-title":"Mult Scler Relat Disord."},{"key":"1246_CR25","doi-asserted-by":"publisher","first-page":"E1939","DOI":"10.1212\/WNL.0000000000009374","volume":"94","author":"A Langer-Gould","year":"2020","unstructured":"Langer-Gould A, Smith JB, Albers KB, Xiang AH, Wu J, Kerezsi EH, et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology. 2020;94:E1939\u201349. https:\/\/doi.org\/10.1212\/WNL.0000000000009374.","journal-title":"Neurology"},{"key":"1246_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANEUROL.2025.2550","author":"A Gavoille","year":"2025","unstructured":"Gavoille A, Rollot F, Casey R, Mathey G, Le Page E, Ciron J, et al. Therapeutic management during pregnancy and relapse risk in women with multiple sclerosis. JAMA Neurol Internet. 2025. https:\/\/doi.org\/10.1001\/JAMANEUROL.2025.2550.","journal-title":"JAMA Neurol Internet."},{"key":"1246_CR27","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1212\/CPJ.0000000000001147\/ASSET\/9FCB4D91-9299-42C7-A213-88FF38BC0B39\/ASSETS\/GRAPHIC\/8TTU1.JPEG","volume":"12","author":"A Galati","year":"2022","unstructured":"Galati A, McElrath T, Bove R. Use of B-cell\u2013depleting therapy in women of childbearing potential with multiple sclerosis and neuromyelitis optica spectrum disorder. Neurol Clin Pract [Internet]. 2022;12:154\u201363. https:\/\/doi.org\/10.1212\/CPJ.0000000000001147\/ASSET\/9FCB4D91-9299-42C7-A213-88FF38BC0B39\/ASSETS\/GRAPHIC\/8TTU1.JPEG.","journal-title":"Neurol Clin Pract [Internet]."},{"key":"1246_CR28","unstructured":"MabThera | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 29]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera. Accessed 29 Apr 2025."},{"key":"1246_CR29","unstructured":"Highlights of prescribing information - rituximab. [cited 2025 Apr 29]; www.fda.gov\/medwatch. Accessed 29 Apr 2025."},{"key":"1246_CR30","unstructured":"Ocrevus | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 29]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ocrevus. Accessed 29 Apr 2025."},{"key":"1246_CR31","unstructured":"FDA, CDER. Highlights of prescribing information - ocrevus. [cited 2025 Apr 29]; www.fda.gov\/medwatch. Accessed 29 Apr 2025."},{"key":"1246_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/J.REUMAE.2016.01.004","volume":"12","author":"L Valor","year":"2016","unstructured":"Valor L, Ovalles-Bonilla JG, Hern\u00e1ndez-Fl\u00f3rez D, L\u00f3pez-Longo FJ. Treatment with monoclonal antibodies and pregnancy in women with systemic inflammatory diseases: a special situation. Reumatolog\u00eda Cl\u00ednica (English Edition). 2016;12:359\u201360. https:\/\/doi.org\/10.1016\/J.REUMAE.2016.01.004.","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"key":"1246_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/DIAGNOSTICS10080583","volume":"10","author":"AM Ciobanu","year":"2020","unstructured":"Ciobanu AM, Dumitru AE, Gica N, Botezatu R, Peltecu G, Panaitescu AM. Benefits and risks of IgG transplacental transfer. Diagnostics [Internet]. 2020;10:583. https:\/\/doi.org\/10.3390\/DIAGNOSTICS10080583.","journal-title":"Diagnostics [Internet]."},{"key":"1246_CR34","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1111\/BCP.14658","volume":"87","author":"E Gibiansky","year":"2020","unstructured":"Gibiansky E, Petry C, Mercier F, G\u00fcnther A, Herman A, Kappos L, et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol. 2020;87:2511. https:\/\/doi.org\/10.1111\/BCP.14658.","journal-title":"Br J Clin Pharmacol"},{"key":"1246_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200349","volume":"12","author":"S Vukusic","year":"2024","unstructured":"Vukusic S, Bove R, Dobson R, McElrath T, Oreja-Guevara C, Pietrasanta C, et al. Pregnancy and infant outcomes in women with multiple sclerosis treated with ocrelizumab. Neurol Neuroimmunol Neuroinflamm [Internet]. 2024;12:e200349. https:\/\/doi.org\/10.1212\/NXI.0000000000200349.","journal-title":"Neurol Neuroimmunol Neuroinflamm [Internet]."},{"key":"1246_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1212\/CON.0000000000001108","volume":"28","author":"RM Bove","year":"2022","unstructured":"Bove RM, Houtchens MK. Pregnancy management in multiple sclerosis and other demyelinating diseases. CONTINUUM Lifelong Learning in Neurology [Internet]. 2022;28:12\u201333. https:\/\/doi.org\/10.1212\/CON.0000000000001108.","journal-title":"CONTINUUM Lifelong Learning in Neurology [Internet]."},{"key":"1246_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","volume":"22","author":"KM Krysko","year":"2023","unstructured":"Krysko KM, Dobson R, Alroughani R, Amato MP, Bove R, Ciplea AI, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350\u201366. https:\/\/doi.org\/10.1016\/S1474-4422(22)00426-4.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1246_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/JNNP-2023-332804","volume":"95","author":"S Thiel","year":"2024","unstructured":"Thiel S, Litvin N, Haben S, Gold R, Hellwig K. Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy. J Neurol Neurosurg Psychiatry. 2024;95(6):561\u201370. https:\/\/doi.org\/10.1136\/JNNP-2023-332804.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1246_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012084","volume":"96","author":"WZ Yeh","year":"2021","unstructured":"Yeh WZ, Widyastuti PA, Van der Walt A, Stankovich J, Havrdova E, Horakova D, et al. Natalizumab, fingolimod, and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis. Neurology. 2021;96:e2989. https:\/\/doi.org\/10.1212\/WNL.0000000000012084.","journal-title":"Neurology"},{"key":"1246_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2022.104038","volume":"66","author":"G Valero-L\u00f3pez","year":"2022","unstructured":"Valero-L\u00f3pez G, Mill\u00e1n-Pascual J, Iniesta-Mart\u00ednez F, Delgado-Mar\u00edn JL, Jimenez-Veiga J, Tejero-Mart\u00edn AB, et al. Treatment with natalizumab during pregnancy in multiple sclerosis: the experience of implementing a clinical practice protocol (NAP-30). Mult Scler Relat Disord. 2022;66:104038. https:\/\/doi.org\/10.1016\/J.MSARD.2022.104038.","journal-title":"Mult Scler Relat Disord"},{"key":"1246_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2024.105605","volume":"86","author":"JD Brown","year":"2024","unstructured":"Brown JD, Muston BT, Massey J. Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2024;86:105605. https:\/\/doi.org\/10.1016\/J.MSARD.2024.105605.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"1246_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/ENE.16587","volume":"32","author":"G Bsteh","year":"2024","unstructured":"Bsteh G, Hoepner R, Gernert JA, Berek K, Gradl C, Kliushnikova D, et al. Switching from natalizumab to <scp>antiCD20<\/scp> monoclonal antibodies: Short transition interval is associated with improved outcome. Eur J Neurol. 2024;32(1):e16587. https:\/\/doi.org\/10.1111\/ENE.16587.","journal-title":"Eur J Neurol"},{"key":"1246_CR43","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200110","author":"K Hellwig","year":"2023","unstructured":"Hellwig K, Tokic M, Thiel S, Hemat S, Timmesfeld N, Ciplea AI, et al. Multiple sclerosis disease activity and disability following cessation of fingolimod for pregnancy. Neurol Neuroimmunol Neuroinflamm. 2023. https:\/\/doi.org\/10.1212\/NXI.0000000000200110.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1246_CR44","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000137","volume":"82","author":"G Karlsson","year":"2014","unstructured":"Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen JA, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82:674. https:\/\/doi.org\/10.1212\/WNL.0000000000000137.","journal-title":"Neurology"},{"key":"1246_CR45","unstructured":"FDA, CDER. Highlights of prescribing information. [cited 2025 Apr 24]; www.fda.gov\/medwatch. Accessed 24 Apr 2025."},{"key":"1246_CR46","unstructured":"Gilenya | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 24]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gilenya. Accessed 24 Apr 2025."},{"key":"1246_CR47","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000453","author":"G Das","year":"2018","unstructured":"Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, et al. Rituximab before and during pregnancy. Neurol Neuroimmunol Neuroinflamm [Internet]. 2018. https:\/\/doi.org\/10.1212\/NXI.0000000000000453.","journal-title":"Neurol Neuroimmunol Neuroinflamm [Internet]"},{"key":"1246_CR48","unstructured":"Lemtrada - referral | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 24]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/lemtrada. Accessed 24 Apr 2025."},{"key":"1246_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102146","volume":"43","author":"J Oh","year":"2020","unstructured":"Oh J, Achiron A, Celius EG, Chambers C, Derwenskus J, Devonshire V, et al. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord. 2020;43:102146. https:\/\/doi.org\/10.1016\/j.msard.2020.102146.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"1246_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000000731","volume":"33","author":"G Varyt\u0117","year":"2021","unstructured":"Varyt\u0117 G, Arlauskien\u0117 A, Rama\u0161auskait\u0117 D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol. 2021;33(5):378. https:\/\/doi.org\/10.1097\/GCO.0000000000000731.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1246_CR51","unstructured":"Mavenclad | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 24]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mavenclad. Accessed 24 Apr 2025."},{"key":"1246_CR52","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/S40264-020-00948-X","volume":"43","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, et al. Pregnancy outcomes during the clinical development program of cladribine in multiple sclerosis: an integrated analysis of safety. Drug Saf. 2020;43:635. https:\/\/doi.org\/10.1007\/S40264-020-00948-X.","journal-title":"Drug Saf"},{"key":"1246_CR53","unstructured":"FDA, CDER. Highlights of prescribing information - cladribine. [cited 2025 May 13]; www.fda.gov\/. Accessed 13 May 2025."},{"key":"1246_CR54","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/13524585221131486\/FORMAT\/EPUB","volume":"29","author":"K Dost-Kovalsky","year":"2023","unstructured":"Dost-Kovalsky K, Thiel S, Ciplea AI, Gold R, Hellwig K. Cladribine and pregnancy in women with multiple sclerosis: the first cohort study. Mult Scler J [Internet]. 2023;29:461\u20135. https:\/\/doi.org\/10.1177\/13524585221131486\/FORMAT\/EPUB.","journal-title":"Mult Scler J [Internet]."},{"key":"1246_CR55","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200438","volume":"12","author":"K Hellwig","year":"2025","unstructured":"Hellwig K, Tilson HH, Thiel S, Ball K, Seebeck J, Danten M, et al. Pregnancy and infant outcomes in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm [Internet]. 2025;12:e200438. https:\/\/doi.org\/10.1212\/NXI.0000000000200438.","journal-title":"Neurol Neuroimmunol Neuroinflamm [Internet]."},{"key":"1246_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/JCM10225401","volume":"10","author":"C Massarotti","year":"2021","unstructured":"Massarotti C, Sbragia E, Gazzo I, Stigliani S, Inglese M, Anserini P. Effect of multiple sclerosis and its treatments on male fertility: cues for future research. J Clin Med. 2021;10:5401. https:\/\/doi.org\/10.3390\/JCM10225401.","journal-title":"J Clin Med"},{"key":"1246_CR57","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/S00415-020-09762-Y\/TABLES\/2","volume":"267","author":"K Hellwig","year":"2020","unstructured":"Hellwig K, Geissbuehler Y, Sabid\u00f3 M, Popescu C, Adamo A, Klinger J, et al. Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. J Neurol [Internet]. 2020;267:1715\u201323. https:\/\/doi.org\/10.1007\/S00415-020-09762-Y\/TABLES\/2.","journal-title":"J Neurol [Internet]."},{"key":"1246_CR58","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420951072\/SUPPL_FILE\/ER-9430_MS_PREG_MANUSCRIPT_FINAL_SUPPLEMENTARY_MATERIAL_TAND_2020-06-10_FINAL_REVISED_CLEAN.PDF","author":"KM Hakkarainen","year":"2020","unstructured":"Hakkarainen KM, Juuti R, Burkill S, Geissb\u00fchler Y, Sabid\u00f3 M, Popescu C, et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord [Internet]. 2020. https:\/\/doi.org\/10.1177\/1756286420951072\/SUPPL_FILE\/ER-9430_MS_PREG_MANUSCRIPT_FINAL_SUPPLEMENTARY_MATERIAL_TAND_2020-06-10_FINAL_REVISED_CLEAN.PDF.","journal-title":"Ther Adv Neurol Disord [Internet]"},{"key":"1246_CR59","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/S40264-022-01168-1","volume":"45","author":"S Kaplan","year":"2022","unstructured":"Kaplan S, Zeygarnik M, Stern T. Pregnancy, fetal, and infant outcomes following maternal exposure to glatiramer acetate during pregnancy and breastfeeding. Drug Saf. 2022;45:345\u201357. https:\/\/doi.org\/10.1007\/S40264-022-01168-1.","journal-title":"Drug Saf"},{"key":"1246_CR60","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/1352458515623366","volume":"22","author":"S Herbstritt","year":"2016","unstructured":"Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, et al. Glatiramer acetate during early pregnancy: a prospective cohort study. Mult Scler J. 2016;22:810\u20136. https:\/\/doi.org\/10.1177\/1352458515623366.","journal-title":"Mult Scler J"},{"key":"1246_CR61","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2016-079","volume":"20","author":"M Sandberg-Wollheim","year":"2018","unstructured":"Sandberg-Wollheim M, Neudorfer O, Grinspan A, Weinstock-Guttman B, Haas J, Izquierdo G, et al. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. Int J MS Care. 2018;20:9. https:\/\/doi.org\/10.7224\/1537-2073.2016-079.","journal-title":"Int J MS Care"},{"key":"1246_CR62","unstructured":"FDA. Highlights of prescribing information. [cited 2025 Apr 24]; www.fda.gov\/medwatch. Accessed 24 Apr 2025."},{"key":"1246_CR63","unstructured":"Annex I Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)."},{"issue":"2","key":"1246_CR64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/S40120-015-0033-1","volume":"4","author":"R Gold","year":"2015","unstructured":"Gold R, Phillips JT, Havrdova E, Bar-Or A, Kappos L, Kim N, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther. 2015;4(2):93\u2013104. https:\/\/doi.org\/10.1007\/S40120-015-0033-1.","journal-title":"Neurol Ther"},{"key":"1246_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2022.103951","author":"G Borriello","year":"2022","unstructured":"Borriello G, Ianniello A. Efficacy, safety and tolerability of dimethylfumarate during pregnancy and breastfeeding. Mult Scler Relat Disord [Internet]. 2022. https:\/\/doi.org\/10.1016\/J.MSARD.2022.103951.","journal-title":"Mult Scler Relat Disord [Internet]"},{"key":"1246_CR66","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1177\/13524585241274600","volume":"30","author":"D Landi","year":"2024","unstructured":"Landi D, Bartolomeo S, Bovis F, Amato MP, Bonavita S, Borriello G, et al. Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy. Mult Scler. 2024;30:1503\u201313. https:\/\/doi.org\/10.1177\/13524585241274600.","journal-title":"Mult Scler"},{"key":"1246_CR67","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/13524585231220232","volume":"30","author":"K Hellwig","year":"2024","unstructured":"Hellwig K, Rog D, McGuigan C, Houtchens MK, Bruen DR, Mokliatchouk O, et al. Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry. Mult Scler J. 2024;30:209\u201315. https:\/\/doi.org\/10.1177\/13524585231220232.","journal-title":"Mult Scler J"},{"key":"1246_CR68","unstructured":"Tecfidera | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 24]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecfidera. Accessed 24 Apr 2025."},{"key":"1246_CR69","unstructured":"NDA 204063-FDA approved labeling text dated highlights of prescribing information- Tecfidera. 2013 [cited 2025 Sep 16]; www.fda.gov\/medwatch. Accessed 16 Sep 2025."},{"key":"1246_CR70","unstructured":"FDA, CDER. Highlights of prescribing information - teriflunomide. [cited 2025 May 13]; www.fda.gov\/medwatch. Accessed 13 May 2025."},{"key":"1246_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.02706","volume":"9","author":"JB Andersen","year":"2018","unstructured":"Andersen JB, Moberg JY, Spelman T, Magyari M. Pregnancy outcomes in men and women treated with teriflunomide. A population-based nationwide Danish register study. Front Immunol. 2018;9:2706. https:\/\/doi.org\/10.3389\/FIMMU.2018.02706.","journal-title":"Front Immunol"},{"key":"1246_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2022.103529","volume":"59","author":"JB Andersen","year":"2022","unstructured":"Andersen JB, Wandall-Holm MF, Magyari M, Elsevier. Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population. Mult Scler Relat Disord. 2022;59:103529. https:\/\/doi.org\/10.1016\/J.MSARD.2022.103529.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1246_CR73","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/S40120-014-0020-Y","volume":"3","author":"BC Kieseier","year":"2014","unstructured":"Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing\u2013remitting multiple sclerosis. Neurol Ther. 2014;3(2):133. https:\/\/doi.org\/10.1007\/S40120-014-0020-Y.","journal-title":"Neurol Ther"},{"key":"1246_CR74","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMOA2415985","volume":"392","author":"J Oh","year":"2025","unstructured":"Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, et al. Tolebrutinib versus teriflunomide in relapsing multiple sclerosis. N Engl J Med [Internet]. 2025;392:1893\u2013904. https:\/\/doi.org\/10.1056\/NEJMOA2415985.","journal-title":"N Engl J Med [Internet]."},{"key":"1246_CR75","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMOA2415988","volume":"392","author":"RJ Fox","year":"2025","unstructured":"Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, et al. Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N Engl J Med. 2025;392:1883\u201392. https:\/\/doi.org\/10.1056\/NEJMOA2415988.","journal-title":"N Engl J Med"},{"key":"1246_CR76","unstructured":"UAE grants world\u2019s first approval for tolebrutinib, breakthrough oral treatment for progressive multiple sclerosis [Internet]. [cited 2025 Oct 2]. https:\/\/trial.medpath.com\/news\/b712cc28d85880c6\/uae-grants-world-s-first-approval-for-tolebrutinib-breakthrough-oral-treatment-for-progressive-multiple-sclerosis. Accessed 2 Oct 2025."},{"key":"1246_CR77","unstructured":"Press release: update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis [Internet]. [cited 2025 Oct 2]. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-09-22-05-00-00-3153624. Accessed 2 Oct 2025."},{"key":"1246_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100831","author":"E Luttwak","year":"2021","unstructured":"Luttwak E, Gurevich-Shapiro A, Azem F, Lishner M, Klieger C, Herishanu Y, et al. Novel agents for the treatment of lymphomas during pregnancy: a comprehensive literature review. Blood Rev. 2021. https:\/\/doi.org\/10.1016\/j.blre.2021.100831.","journal-title":"Blood Rev"},{"key":"1246_CR79","unstructured":"Imbruvica | European Medicines Agency (EMA) [Internet]. [cited 2025 May 3]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imbruvica. Accessed 3 May 2025."},{"key":"1246_CR80","unstructured":"Calquence | European Medicines Agency (EMA) [Internet]. [cited 2025 May 3]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/calquence. Accessed 3 May 2025."},{"key":"1246_CR81","unstructured":"Highlights of prescribing information - acalabrutinib. [cited 2025 May 3]; www.fda.gov\/medwatch. Accessed 3 May 2025."},{"key":"1246_CR82","unstructured":"FDA, CDER. Highlights of prescribing information - ibrutonib. [cited 2025 May 3]; www.fda.gov\/medwatch. Accessed 3 May 2025."},{"key":"1246_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102541","author":"MK Houtchens","year":"2020","unstructured":"Houtchens MK, Edwards NC, Hayward B, Mahony MC, Phillips AL. Live birth rates, infertility diagnosis, and infertility treatment in women with and without multiple sclerosis: data from an administrative claims database. Mult Scler Relat Disord. 2020. https:\/\/doi.org\/10.1016\/j.msard.2020.102541.","journal-title":"Mult Scler Relat Disord"},{"key":"1246_CR84","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/S40263-023-01036-1","volume":"37","author":"M Sparaco","year":"2023","unstructured":"Sparaco M, Carbone L, Landi D, Ingrasciotta Y, Di Girolamo R, Vitturi G, et al. Assisted reproductive technology and disease management in infertile women with multiple sclerosis. CNS Drugs. 2023;37:849. https:\/\/doi.org\/10.1007\/S40263-023-01036-1.","journal-title":"CNS Drugs"},{"key":"1246_CR85","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/S40120-023-00439-Y","volume":"12","author":"C Oreja-Guevara","year":"2023","unstructured":"Oreja-Guevara C, Rabanal A, Rodr\u00edguez CH, Benito YA, Bilbao MM, G\u00f3nzalez-Suarez I, et al. Assisted reproductive techniques in multiple sclerosis: recommendations from an expert panel. Neurol Ther [Internet]. 2023;12:427. https:\/\/doi.org\/10.1007\/S40120-023-00439-Y.","journal-title":"Neurol Ther [Internet]."},{"issue":"5","key":"1246_CR86","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/ANA.23745","volume":"72","author":"J Correale","year":"2012","unstructured":"Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol. 2012;72(5):682\u201394. https:\/\/doi.org\/10.1002\/ANA.23745.","journal-title":"Ann Neurol"},{"key":"1246_CR87","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/JNNP-2012-302235","volume":"83","author":"L Michel","year":"2012","unstructured":"Michel L, Foucher Y, Vukusic S, Confavreux C, De S\u00e8ze J, Brassat D, et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry. 2012;83:796\u2013802. https:\/\/doi.org\/10.1136\/JNNP-2012-302235.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1246_CR88","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000177937","volume":"61","author":"K Hellwig","year":"2009","unstructured":"Hellwig K, Schimrigk S, Beste C, M\u00fcller T, Gold R. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol. 2009;61(2):65\u20138. https:\/\/doi.org\/10.1159\/000177937.","journal-title":"Eur Neurol"},{"key":"1246_CR89","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/S00415-008-0607-2","volume":"255","author":"K Hellwig","year":"2008","unstructured":"Hellwig K, Beste C, Brune N, Haghikia A, M\u00fcller T, Schimrigk S, et al. Increased MS relapse rate during assisted reproduction technique. J Neurol. 2008;255:592\u20133. https:\/\/doi.org\/10.1007\/S00415-008-0607-2.","journal-title":"J Neurol"},{"key":"1246_CR90","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1212\/01.WNL.0000208521.10685.A6","volume":"66","author":"DA Laplaud","year":"2006","unstructured":"Laplaud DA, Leray E, Barri\u00e8re P, Wiertlewski S, Moreau T. Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology [Internet]. 2006;66:1280\u20131. https:\/\/doi.org\/10.1212\/01.WNL.0000208521.10685.A6.","journal-title":"Neurology [Internet]."},{"key":"1246_CR91","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200106","volume":"10","author":"EL Graham","year":"2023","unstructured":"Graham EL, Bakkensen JB, Anderson A, Lancki N, Davidson A, Giraldo GP, et al. Inflammatory activity after diverse fertility treatments. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200106. https:\/\/doi.org\/10.1212\/NXI.0000000000200106.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1246_CR92","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/WCO.0000000000001275","volume":"37","author":"MK Houtchens","year":"2024","unstructured":"Houtchens MK. Pregnancy and reproductive health in women with multiple sclerosis: an update. Curr Opin Neurol. 2024;37:202\u201311. https:\/\/doi.org\/10.1097\/WCO.0000000000001275.","journal-title":"Curr Opin Neurol"},{"key":"1246_CR93","doi-asserted-by":"publisher","first-page":"E102","DOI":"10.1097\/AOG.0000000000002237","volume":"130","author":"YY El-Sayed","year":"2017","unstructured":"El-Sayed YY, Borders AEB, Gyamfi-Bannerman C. Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2017;130:E102\u20139. https:\/\/doi.org\/10.1097\/AOG.0000000000002237.","journal-title":"Obstet Gynecol"},{"key":"1246_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103449","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang J, Feng J. Multiple sclerosis and pregnancy: pathogenesis, influencing factors, and treatment options. Autoimmun Rev. 2023. https:\/\/doi.org\/10.1016\/j.autrev.2023.103449.","journal-title":"Autoimmun Rev"},{"key":"1246_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105435","author":"B Yamout","year":"2024","unstructured":"Yamout B, Al-Jumah M, Sahraian MA, Almalik Y, Khaburi JA, Shalaby N, et al. Consensus recommendations for diagnosis and treatment of multiple sclerosis: 2023 revision of the MENACTRIMS guidelines. Mult Scler Relat Disord. 2024. https:\/\/doi.org\/10.1016\/j.msard.2024.105435.","journal-title":"Mult Scler Relat Disord"},{"key":"1246_CR96","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejogrb.2020.08.013","volume":"253","author":"N Liu","year":"2020","unstructured":"Liu N, Wang J, Chen D, Sun W, Li P, Zhang W. Effects of exercise on pregnancy and postpartum fatigue: a systematic review and meta-analysis. Eur J Obstetr Gynecol Reprod Biol [Internet]. 2020;253:285\u201395. https:\/\/doi.org\/10.1016\/j.ejogrb.2020.08.013.","journal-title":"Eur J Obstetr Gynecol Reprod Biol [Internet]"},{"key":"1246_CR97","doi-asserted-by":"publisher","DOI":"10.5935\/1984-0063.20200091","volume":"14","author":"F Effati-Daryani","year":"2021","unstructured":"Effati-Daryani F, Mohammad-Alizadeh-Charandabi S, Mohammadi A, Zarei S, Mirghafourvand M. Fatigue and sleep quality in different trimesters of pregnancy. Sleep Sci. 2021;14:69. https:\/\/doi.org\/10.5935\/1984-0063.20200091.","journal-title":"Sleep Sci"},{"key":"1246_CR98","doi-asserted-by":"publisher","first-page":"106596","DOI":"10.1016\/J.CLINBIOMECH.2025.106596","volume":"127","author":"BR Dumke","year":"2025","unstructured":"Dumke BR, Theilen LH, Shaw JM, Foreman KB, Dibble LE, Fino PC. Dynamic balance and mobility during pregnancy. Clin Biomech [Internet]. 2025;127:106596. https:\/\/doi.org\/10.1016\/J.CLINBIOMECH.2025.106596.","journal-title":"Clin Biomech [Internet]"},{"issue":"2","key":"1246_CR99","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/AOGS.12544","volume":"94","author":"LI Iezzoni","year":"2014","unstructured":"Iezzoni LI, Wint AJ, Smeltzer SC, Ecker JL. Effects of disability on pregnancy experiences among women with impaired mobility. Acta Obstet Gynecol Scand. 2014;94(2):133\u201340. https:\/\/doi.org\/10.1111\/AOGS.12544.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1246_CR100","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1177\/13524585211041108","volume":"28","author":"KM Krysko","year":"2022","unstructured":"Krysko KM, Anderson A, Singh J, McPolin K, Rutatangwa A, Rowles W, et al. Risk factors for peripartum depression in women with multiple sclerosis. Mult Scler J. 2022;28:970\u20139. https:\/\/doi.org\/10.1177\/13524585211041108.","journal-title":"Mult Scler J"},{"key":"1246_CR101","doi-asserted-by":"publisher","DOI":"10.1177\/1745506519844044","author":"J Slomian","year":"2019","unstructured":"Slomian J, Honvo G, Emonts P, Reginster JY, Bruy\u00e8re O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. Womens Health. 2019. https:\/\/doi.org\/10.1177\/1745506519844044.","journal-title":"Womens Health"},{"key":"1246_CR102","doi-asserted-by":"publisher","first-page":"E2789","DOI":"10.1212\/WNL.0000000000012062\/ASSET\/AEE4B754-43F2-4873-AAF8-F8919E8E831B\/ASSETS\/GRAPHIC\/4TTU1.GIF","volume":"96","author":"K Eid","year":"2021","unstructured":"Eid K, Torkildsen \u00d8F, Aarseth J, Flemmen H\u00d8, Holm\u00f8y T, Lorentzen \u00c5R, et al. Perinatal depression and anxiety in women with multiple sclerosis: a population-based cohort study. Neurology Lippincott Williams and Wilkins. 2021;96:E2789\u2013800. https:\/\/doi.org\/10.1212\/WNL.0000000000012062\/ASSET\/AEE4B754-43F2-4873-AAF8-F8919E8E831B\/ASSETS\/GRAPHIC\/4TTU1.GIF.","journal-title":"Neurology. Lippincott Williams and Wilkins"},{"key":"1246_CR103","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1177\/1352458516631037","volume":"22","author":"N Razaz","year":"2016","unstructured":"Razaz N, Tremlett H, Marrie RA, Joseph KS. Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children. Mult Scler. 2016;22:1830\u201340. https:\/\/doi.org\/10.1177\/1352458516631037.","journal-title":"Mult Scler"},{"key":"1246_CR104","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/S11920-022-01372-X","volume":"24","author":"LG Lebin","year":"2022","unstructured":"Lebin LG, Novick AM. Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: an updated review on risks to mother, fetus, and child. Curr Psychiatry Rep [Internet]. 2022;24:687. https:\/\/doi.org\/10.1007\/S11920-022-01372-X.","journal-title":"Curr Psychiatry Rep [Internet]."},{"key":"1246_CR105","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/ARCHDISCHILD-2023-326049","volume":"109","author":"MC Cornet","year":"2024","unstructured":"Cornet MC, Wu YW, Forquer H, Avalos LA, Sriram A, Scheffler AW, et al. Maternal treatment with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation: a population-based cohort study. Arch Dis Child Fetal Neonatal Ed. 2024;109:294\u2013300. https:\/\/doi.org\/10.1136\/ARCHDISCHILD-2023-326049.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"1246_CR106","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1097\/AOG.0000000000005202","volume":"141","author":"ES Miller","year":"2023","unstructured":"Miller ES, Metz T, Moore Simas TA, Hoffman MC, Byatt N, Roussos-Ross K. Treatment and management of mental health conditions during pregnancy and postpartum: ACOG Clinical Practice Guideline No. 5. Obstet Gynecol. 2023;141:1262\u201388. https:\/\/doi.org\/10.1097\/AOG.0000000000005202.","journal-title":"Obstet Gynecol"},{"key":"1246_CR107","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/JAMA.2019.20008","volume":"323","author":"P Damkier","year":"2020","unstructured":"Damkier P, Broe A. First-trimester pregnancy exposure to modafinil and risk of congenital malformations. JAMA. 2020;323:374\u20136. https:\/\/doi.org\/10.1001\/JAMA.2019.20008.","journal-title":"JAMA"},{"issue":"5","key":"1246_CR108","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/ACPS.13643","volume":"150","author":"M Onken","year":"2024","unstructured":"Onken M, Lohse L, Coulm B, Beghin D, Richardson JL, Bermejo-S\u00e1nchez E, et al. Effects of maternal modafinil treatment on fetal development and neonatal growth parameters \u2014 a multicenter case series of the European Network of Teratology Information Services (ENTIS). Acta Psychiatr Scand. 2024;150(5):372\u201384. https:\/\/doi.org\/10.1111\/ACPS.13643.","journal-title":"Acta Psychiatr Scand"},{"key":"1246_CR109","unstructured":"Modafinil - referral | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 24]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/modafinil. Accessed 24 Apr 2025."},{"key":"1246_CR110","unstructured":"NDA 20-717 PROVIGIL\u00ae (modafinil) Tablets FDA PROVIGIL\u00ae (modafinil) Tablets [C-IV] Rx Only DESCRIPTION. 2007;"},{"key":"1246_CR111","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1067\/MCP.2002.121217","volume":"71","author":"P Robertson","year":"2002","unstructured":"Robertson P, Hellriegel ET, Arora S, Nelson M. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther. 2002;71:46\u201356. https:\/\/doi.org\/10.1067\/MCP.2002.121217.","journal-title":"Clin Pharmacol Ther"},{"key":"1246_CR112","unstructured":"FDA, CDER. Highlights of prescribing information - amantadine. [cited 2025 Sep 14]; http:\/\/www.fda.gov\/medwatch. Accessed 14 Sep 2025."},{"key":"1246_CR113","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/J.PARKRELDIS.2017.05.007","volume":"40","author":"M Seier","year":"2017","unstructured":"Seier M, Hiller A. Parkinson\u2019s disease and pregnancy: an updated review. Parkinsonism Relat Disord. 2017;40:11\u20137. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2017.05.007.","journal-title":"Parkinsonism Relat Disord"},{"key":"1246_CR114","unstructured":"Methylphenidate - referral | European Medicines Agency (EMA) [Internet]. [cited 2025 Sep 14]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/methylphenidate. Accessed 14 Sep 2025."},{"key":"1246_CR115","unstructured":"FDA, CDER. Highlights of prescribing information - methylphenidate. [cited 2025 Sep 14]; www.fda.gov\/medwatch. Accessed 14 Sep 2025."},{"key":"1246_CR116","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2024.43648","volume":"7","author":"E Di Giacomo","year":"2024","unstructured":"Di Giacomo E, Confalonieri V, Tofani F, Clerici M. Methylphenidate and atomoxetine in pregnancy and possible adverse fetal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2024;7:e2443648\u2013e2443648. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2024.43648.","journal-title":"JAMA Netw Open"},{"key":"1246_CR117","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(20)30354-9","volume":"20","author":"B Nourbakhsh","year":"2020","unstructured":"Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomized, crossover, double-blind trial. Lancet Neurol [Internet]. 2020;20:38. https:\/\/doi.org\/10.1016\/S1474-4422(20)30354-9.","journal-title":"Lancet Neurol [Internet]."},{"key":"1246_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2018.03.024","volume":"52","author":"MA Chalah","year":"2018","unstructured":"Chalah MA, Ayache SS. Cognitive behavioral therapies and multiple sclerosis fatigue: A review of literature. J Clin Neurosci [Internet]. 2018;52:1\u20134. https:\/\/doi.org\/10.1016\/j.jocn.2018.03.024.","journal-title":"J Clin Neurosci [Internet]."},{"issue":"11","key":"1246_CR119","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1177\/1352458521996002","volume":"27","author":"AM Harrison","year":"2021","unstructured":"Harrison AM, Safari R, Mercer T, Picariello F, van der Linden ML, White C, et al. Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis. Mult Scler J. 2021;27(11):1657\u201378. https:\/\/doi.org\/10.1177\/1352458521996002.","journal-title":"Mult Scler J"},{"key":"1246_CR120","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/PSY.0000000000000559","volume":"80","author":"PJ O\u2019Connor","year":"2018","unstructured":"O\u2019Connor PJ, Poudevigne MS, Johnson KE, De Araujo JB, Ward-Ritacco CL. Effects of resistance training on fatigue-related domains of quality of life and mood during pregnancy: a randomized trial in pregnant women with increased risk of back pain. Psychosom Med [Internet]. 2018;80:327\u201332. https:\/\/doi.org\/10.1097\/PSY.0000000000000559.","journal-title":"Psychosom Med [Internet]."},{"key":"1246_CR121","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejogrb.2020.08.013","volume":"253","author":"N Liu","year":"2020","unstructured":"Liu N, Wang J, Chen D, Sun W, Li P, Zhang W. Effects of exercise on pregnancy and postpartum fatigue: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;253:285\u201395. https:\/\/doi.org\/10.1016\/j.ejogrb.2020.08.013.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1246_CR122","doi-asserted-by":"publisher","first-page":"106596","DOI":"10.1016\/J.CLINBIOMECH.2025.106596","volume":"127","author":"BR Dumke","year":"2025","unstructured":"Dumke BR, Theilen LH, Shaw JM, Foreman KB, Dibble LE, Fino PC. Dynamic balance and mobility during pregnancy. Clin Biomech [Internet]. 2025;127:106596. https:\/\/doi.org\/10.1016\/J.CLINBIOMECH.2025.106596.","journal-title":"Clin Biomech [Internet]."},{"key":"1246_CR123","unstructured":"Fampyra | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 24]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fampyra. Accessed 24 Apr 2025."},{"key":"1246_CR124","unstructured":"FDA. Highlights of prescribing information - Dalfampradine. [cited 2025 Sep 16]; www.fda.gov\/medwatch. Accessed 16 Sep 2025."},{"key":"1246_CR125","unstructured":"FDA, CDER. Highlights of prescribing information - baclofen. [cited 2025 Sep 16]; www.fda.gov\/medwatch. Accessed 16 Sep 2025."},{"key":"1246_CR126","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/S11910-018-0857-Z","volume":"18","author":"J Tornic","year":"2018","unstructured":"Tornic J, Panicker JN. The management of lower urinary tract dysfunction in multiple sclerosis. Curr Neurol Neurosci Rep [Internet]. 2018;18:54. https:\/\/doi.org\/10.1007\/S11910-018-0857-Z.","journal-title":"Curr Neurol Neurosci Rep [Internet]."},{"key":"1246_CR127","doi-asserted-by":"publisher","first-page":"172","DOI":"10.7224\/1537-2073.2014-031","volume":"17","author":"V Block","year":"2015","unstructured":"Block V, Rivera M, Melnick M, Allen DD. Do physical therapy interventions affect urinary incontinence and quality of life in people with multiple sclerosis? Int J MS Care. 2015;17:172\u201380. https:\/\/doi.org\/10.7224\/1537-2073.2014-031.","journal-title":"Int J MS Care"},{"key":"1246_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102703","author":"VJ Block","year":"2021","unstructured":"Block VJ, Mestas O, Anderson A, Singh J, Wylie L, Guo CY, et al. Underutilization of physical therapy for symptomatic women with MS during and following pregnancy. Mult Scler Relat Disord. 2021. https:\/\/doi.org\/10.1016\/j.msard.2020.102703.","journal-title":"Mult Scler Relat Disord"},{"key":"1246_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/MEDICINA57040387","volume":"57","author":"KE Romeikien\u0117","year":"2021","unstructured":"Romeikien\u0117 KE, Bartkevi\u010dien\u0117 D. Pelvic-floor dysfunction prevention in prepartum and postpartum periods. Medicina (B Aires). 2021;57:387. https:\/\/doi.org\/10.3390\/MEDICINA57040387.","journal-title":"Medicina (B Aires)"},{"key":"1246_CR130","unstructured":"DITROPAN \u00ae (oxybutynin chloride) Tablets and Syrup DESCRIPTION. [cited 2025 Apr 24]; https:\/\/www.fda.gov\/drugsatfda. Accessed 24 Apr 2025."},{"issue":"2","key":"1246_CR131","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/S00192-018-3620-8","volume":"30","author":"E Andretta","year":"2019","unstructured":"Andretta E, Landi LM, Cianfrocca M, Manassero A, Risi O, Artuso G. Bladder management during pregnancy in women with spinal-cord injury: an observational, multicenter study. Int Urogynecol J. 2019;30(2):293\u2013300. https:\/\/doi.org\/10.1007\/S00192-018-3620-8.","journal-title":"Int Urogynecol J"},{"key":"1246_CR132","unstructured":"Betmiga | European Medicines Agency (EMA) [Internet]. [cited 2025 May 13]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/betmiga. Accessed 13 May 2025."},{"key":"1246_CR133","unstructured":"Highlights of prescribing information - mirabegron. [cited 2025 May 13]; www.fda.gov\/medwatch. Accessed 13 May 2025."},{"key":"1246_CR134","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/ACN3.51893","volume":"10","author":"A Anderson","year":"2023","unstructured":"Anderson A, Rowles W, Poole S, Balan A, Bevan C, Brandstadter R, et al. Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Ann Clin Transl Neurol. 2023;10:2053\u201364. https:\/\/doi.org\/10.1002\/ACN3.51893.","journal-title":"Ann Clin Transl Neurol"},{"key":"1246_CR135","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200328","volume":"11","author":"WZ Yeh","year":"2024","unstructured":"Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, et al. Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies. Neurol Neuroimmunol Neuroinflamm. 2024;11:e200328. https:\/\/doi.org\/10.1212\/NXI.0000000000200328.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1246_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2024.105557","volume":"85","author":"O Sahloul","year":"2024","unstructured":"Sahloul O, Louapre C, Beigneux Y, Lubetzki C, Maillart E, Roux T. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies. Mult Scler Relat Disord [Internet]. 2024;85:105557. https:\/\/doi.org\/10.1016\/J.MSARD.2024.105557.","journal-title":"Mult Scler Relat Disord [Internet]"},{"key":"1246_CR137","unstructured":"Drugs and Lactation Database (LactMed) - Record Format. National Institute of Child Health and Human Development; 2006 [cited 2025 Apr 22]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547442\/. Accessed 22 Apr 2025."},{"key":"1246_CR138","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211193","author":"R Bove","year":"2025","unstructured":"Bove R, Oreja-Guevara C, Vukusic S, Shah A, Graham E, McElrath T, et al. Placental and breastmilk transfer of ocrelizumab from women with multiple sclerosis to infants and the potential impact on B-cell levels: primary analysis of the prospective, multicenter, open-label, phase IV studies MINORE and SOPRANINO (PL4.004). Neurology. 2025. https:\/\/doi.org\/10.1212\/WNL.0000000000211193.","journal-title":"Neurology"},{"key":"1246_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2024.106136","volume":"92","author":"K Hellwig","year":"2024","unstructured":"Hellwig K, Oreja-Guevara C, Dobson R, Vukusic S, Shah A, Graham E, et al. 175. B-cell levels in infants of lactating women with multiple sclerosis receiving ocrelizumab: SOPRANINO primary results. Mult Scler Relat Disord. 2024;92:106136. https:\/\/doi.org\/10.1016\/J.MSARD.2024.106136.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"1246_CR140","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/JNNP-2022-329545","volume":"94","author":"BE R\u00f8d","year":"2023","unstructured":"R\u00f8d BE, Torkildsen \u00d8, Myhr KM, B\u00f8 L, Wergeland S. Safety of breast feeding during rituximab treatment in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023;94(1):38\u201341. https:\/\/doi.org\/10.1136\/JNNP-2022-329545.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1246_CR141","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241307165","author":"L Witt","year":"2025","unstructured":"Witt L, Dost-Kovalsky K, Friedmann N, Bast N, Haben S, Oganowski T, et al. Ofatumumab-exposed breastfeeding in multiple sclerosis patients. Mult Scler J. 2025. https:\/\/doi.org\/10.1177\/13524585241307165.","journal-title":"Mult Scler J"},{"key":"1246_CR142","doi-asserted-by":"publisher","first-page":"851413","DOI":"10.3389\/FNEUR.2022.851413\/BIBTEX","volume":"13","author":"F Capone","year":"2022","unstructured":"Capone F, Albanese A, Quadri G, Di Lazzaro V, Falato E, Cortese A, et al. Disease-modifying drugs and breastfeeding in multiple sclerosis: a narrative literature review. Front Neurol [Internet]. 2022;13:851413. https:\/\/doi.org\/10.3389\/FNEUR.2022.851413\/BIBTEX.","journal-title":"Front Neurol [Internet]."},{"key":"1246_CR143","unstructured":"Natalizumab. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2025 [cited 2025 Apr 24]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501613\/. Accessed 24 Apr 2025."},{"key":"1246_CR144","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000723","volume":"7","author":"AI Ciplea","year":"2020","unstructured":"Ciplea AI, Langer-Gould A, De Vries A, Schaap T, Thiel S, Ringelstein M, et al. Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm [Internet]. 2020;7:e723. https:\/\/doi.org\/10.1212\/NXI.0000000000000723.","journal-title":"Neurol Neuroimmunol Neuroinflamm [Internet]."},{"key":"1246_CR145","unstructured":"FDA. Highlights of prescribing information. [cited 2025 Apr 24]; www.fda.gov\/medwatch. Accessed 24 Apr 2025"},{"key":"1246_CR146","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/THY.2016.0457","volume":"27","author":"EK Alexander","year":"2017","unstructured":"Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid [Internet]. 2017;27:315\u201389. https:\/\/doi.org\/10.1089\/THY.2016.0457.","journal-title":"Thyroid [Internet]."},{"key":"1246_CR147","unstructured":"Interferon Beta. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2025 [cited 2025 Apr 24]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501168\/. Accessed 24 Apr 2025."},{"key":"1246_CR148","unstructured":"Glatiramer. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2025 [cited 2025 Apr 24]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501167\/. Accessed 24 Apr 2025."},{"key":"1246_CR149","unstructured":"Dimethyl fumarate. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2024 [cited 2025 Apr 11]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500735\/. Accessed 11 Apr 2025."},{"key":"1246_CR150","unstructured":"Cladribine. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2023 [cited 2025 Apr 24]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500815\/. Accessed 24 Apr 2025."},{"key":"1246_CR151","unstructured":"Fingolimod. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2021 [cited 2025 Apr 22]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501729\/. Accessed 22 Apr 2025."},{"key":"1246_CR152","doi-asserted-by":"publisher","unstructured":"Wiendl H. Teriflunomide. Psychopharmakotherapie [Internet]. National Institute of Child Health and Human Development; 2021;21:3\u20136. https:\/\/doi.org\/10.1310\/hpj4803-231","DOI":"10.1310\/hpj4803-231"},{"issue":"1","key":"1246_CR153","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1756285608100416","volume":"2","author":"K Hellwig","year":"2009","unstructured":"Hellwig K, Beste C, Chan A, Schimrigk S. Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther Adv Neurol Disord. 2009;2(1):7\u201311. https:\/\/doi.org\/10.1177\/1756285608100416.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1246_CR154","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/J.IJGO.2016.01.008","volume":"134","author":"E Brandt-Wouters","year":"2016","unstructured":"Brandt-Wouters E, Gerlach OHH, Hupperts RMM. The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis. Int J Gynaecol Obstet. 2016;134(2):194\u20136. https:\/\/doi.org\/10.1016\/J.IJGO.2016.01.008.","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"1246_CR155","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF00878527","volume":"243","author":"A Achiron","year":"1996","unstructured":"Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol. 1996;243(1):25\u20138. https:\/\/doi.org\/10.1007\/BF00878527.","journal-title":"J Neurol"},{"key":"1246_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2019.101519","volume":"38","author":"A Horvat Ledinek","year":"2020","unstructured":"Horvat Ledinek A, Brecl Jakob G, Jer\u0161e J, Ru\u0161ka B, Pavi\u010di\u0107 T, Gabeli\u0107 T, et al. Intravenous immunoglobulins for the prevention of postpartum relapses in multiple sclerosis. Mult Scler Relat Disord. 2020;38:101519. https:\/\/doi.org\/10.1016\/J.MSARD.2019.101519.","journal-title":"Mult Scler Relat Disord"},{"key":"1246_CR157","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/S00415-004-0495-Z","volume":"251","author":"A Achiron","year":"2004","unstructured":"Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol. 2004;251:1133\u20137. https:\/\/doi.org\/10.1007\/S00415-004-0495-Z.","journal-title":"J Neurol"},{"key":"1246_CR158","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1080\/07399332.2014.948627","volume":"36","author":"YD Fragoso","year":"2015","unstructured":"Fragoso YD, Adoni T, Alves-Leon SV, Azambuja ND, Barreira AA, Brooks JBB, et al. Postpartum treatment with immunoglobulin does not prevent relapses of multiple sclerosis in the mother. Health Care Women Int [Internet]. 2015;36:1072\u201380. https:\/\/doi.org\/10.1080\/07399332.2014.948627.","journal-title":"Health Care Women Int [Internet]"},{"key":"1246_CR159","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/J.1399-3038.2008.00828.X","volume":"20","author":"P Palmeira","year":"2009","unstructured":"Palmeira P, Costa-Carvalho BT, Arslanian C, Pontes GN, Nagao AT, Carneiro-Sampaio MMS. Transfer of antibodies across the placenta and in breast milk from mothers on intravenous immunoglobulin. Pediatr Allergy Immunol. 2009;20:528\u201335. https:\/\/doi.org\/10.1111\/J.1399-3038.2008.00828.X.","journal-title":"Pediatr Allergy Immunol"},{"key":"1246_CR160","unstructured":"BIVIGAM | FDA [Internet]. [cited 2025 Sep 11]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/bivigam. Accessed 11 Sep 2025."},{"key":"1246_CR161","unstructured":"Kiovig | European Medicines Agency (EMA) [Internet]. [cited 2025 Sep 11]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kiovig. Accessed 11 Sep 2025."},{"key":"1246_CR162","unstructured":"Sertraline. Drugs and Lactation Database (LactMed) [Internet]. National Institute of Child Health and Human Development; 2025 [cited 2025 Apr 24]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501191\/. Accessed 24 Apr 2025."},{"key":"1246_CR163","unstructured":"Zoloft - referral | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 24]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/zoloft. Accessed 24 Apr 2025."},{"key":"1246_CR164","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1212\/WNL.0000000000002174","volume":"85","author":"RA Marrie","year":"2015","unstructured":"Marrie RA, Fisk JD, Tremlett H, Wolfson C, Warren S, Tennakoon A, et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology. 2015;85:1972\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000002174.","journal-title":"Neurology"},{"key":"1246_CR165","doi-asserted-by":"publisher","first-page":"1394380","DOI":"10.3389\/FPUBH.2024.1394380\/FULL","volume":"12","author":"BA Baattaiah","year":"2024","unstructured":"Baattaiah BA, Alharbi MD, Aldhahi MI, Khan F. Factors associated with postpartum fatigue: an exploration of the moderating role of resilience. Front Public Health. 2024;12:1394380. https:\/\/doi.org\/10.3389\/FPUBH.2024.1394380\/FULL.","journal-title":"Front Public Health"},{"key":"1246_CR166","unstructured":"Modafinil. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2023 [cited 2025 Apr 11]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513058\/. Accessed 11 Apr 2025."},{"key":"1246_CR167","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.5664\/JCSM.7546","volume":"14","author":"S Aurora","year":"2018","unstructured":"Aurora S, Aurora N, Datta P, Rewers-Felkins K, Baker T, Hale TW. Evaluating transfer of modafinil into human milk during lactation: a case report. J Clin Sleep Med. 2018;14:2087\u20139. https:\/\/doi.org\/10.5664\/JCSM.7546.","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"1246_CR168","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/08903344221134273","volume":"39","author":"C Leggett","year":"2023","unstructured":"Leggett C, Ritchie U, Costi L, Elliot D, Mangoni AA, Hague WM. Infant exposure to armodafinil through human milk following maternal use of modafinil. J Hum Lact. 2023;39(2):218\u201322. https:\/\/doi.org\/10.1177\/08903344221134273.","journal-title":"J Hum Lact"},{"key":"1246_CR169","unstructured":"Amantadine. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2025 [cited 2025 Sep 14]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501308\/. Accessed 14 Sep 2025."},{"key":"1246_CR170","unstructured":"Methylphenidate. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2025 [cited 2025 Sep 14]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501310\/. Accessed 14 Sep 2025."},{"key":"1246_CR171","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/J.GAITPOST.2024.03.011","volume":"110","author":"M Fukano","year":"2024","unstructured":"Fukano M, Nomura Y, Tsukahara Y. Does the pregnancy-related adaptation of gait biomechanics after childbirth recover to its pre-pregnancy state? A systematic review. Gait Posture [Internet]. 2024;110:110\u201321. https:\/\/doi.org\/10.1016\/J.GAITPOST.2024.03.011.","journal-title":"Gait Posture [Internet]"},{"key":"1246_CR172","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.gaitpost.2019.12.017","volume":"76","author":"SA Rothwell","year":"2020","unstructured":"Rothwell SA, Eckland CB, Campbell N, Connolly CP, Catena RD. An analysis of postpartum walking balance and the correlations to anthropometry. Gait Posture. 2020;76:270\u20136. https:\/\/doi.org\/10.1016\/j.gaitpost.2019.12.017.","journal-title":"Gait Posture"},{"issue":"1","key":"1246_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41598-018-20648-Y","volume":"8","author":"Q Mei","year":"2018","unstructured":"Mei Q, Gu Y, Fernandez J. Alterations of pregnant gait during pregnancy and post-partum. Sci Rep. 2018;8(1):1\u20137. https:\/\/doi.org\/10.1038\/S41598-018-20648-Y.","journal-title":"Sci Rep"},{"key":"1246_CR174","unstructured":"Baclofen. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2024 [cited 2025 Apr 23]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501201\/. Accessed 23 Apr 2025."},{"key":"1246_CR175","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/XEB.0000000000000391","volume":"21","author":"I Ryht\u00e4","year":"2023","unstructured":"Ryht\u00e4 I, Axelin A, Parisod H, Holopainen A, Hamari L. Effectiveness of exercise interventions on urinary incontinence and pelvic organ prolapse in pregnant and postpartum women: umbrella review and clinical guideline development. JBI Evid Implement. 2023;21:394\u2013408. https:\/\/doi.org\/10.1097\/XEB.0000000000000391.","journal-title":"JBI Evid Implement"},{"issue":"1","key":"1246_CR176","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ajog.2022.07.060","volume":"228","author":"AC Nutaitis","year":"2023","unstructured":"Nutaitis AC, Meckes NA, Madsen AM, Toal CT, Menhaji K, Carter-Brooks CM, et al. Postpartum urinary retention: an expert review. Am J Obstet Gynecol. 2023;228(1):14\u201321. https:\/\/doi.org\/10.1016\/j.ajog.2022.07.060.","journal-title":"Am J Obstet Gynecol"},{"key":"1246_CR177","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/S00192-005-0012-7\/METRICS","volume":"17","author":"A Durufle","year":"2006","unstructured":"Durufle A, Petrilli S, Nicolas B, Robineau S, Guill\u00e9 F, Edan G, et al. Effects of pregnancy and child birth on urinary symptoms and urodynamics in women with multiple sclerosis. Int Urogynecol J [Internet]. 2006;17:352\u20135. https:\/\/doi.org\/10.1007\/S00192-005-0012-7\/METRICS.","journal-title":"Int Urogynecol J [Internet]."},{"key":"1246_CR178","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/S00192-021-04939-Z","volume":"33","author":"D Zhu","year":"2022","unstructured":"Zhu D, Xia Z, Yang Z. Effectiveness of physiotherapy for lower urinary tract symptoms in postpartum women: systematic review and meta-analysis. Int Urogynecol J. 2022;33:507\u201321. https:\/\/doi.org\/10.1007\/S00192-021-04939-Z.","journal-title":"Int Urogynecol J"},{"key":"1246_CR179","doi-asserted-by":"publisher","unstructured":"Dwyer J, Tafuri SM, LaGrange CA. Oxybutynin. xPharm: The Comprehensive Pharmacology Reference [Internet]. 2023 [cited 2025 Apr 8];1\u201313. https:\/\/doi.org\/10.1016\/B978-008055232-3.64278-3","DOI":"10.1016\/B978-008055232-3.64278-3"},{"key":"1246_CR180","unstructured":"Oxybutinyn. National Institute of Child Health and Human Development; 2018 [cited 2025 Apr 24]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501668\/. Accessed 24 Apr 2025."},{"key":"1246_CR181","unstructured":"Kentera (previously Oxybutynin Nicobrand) | European Medicines Agency (EMA) [Internet]. [cited 2025 Apr 24]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kentera. Accessed 24 Apr 2025."},{"key":"1246_CR182","unstructured":"Highlights of prescribing information - oxybutynin. [cited 2025 Sep 16]; www.fda.gov\/medwatch. Accessed 16 Sep 2025."},{"key":"1246_CR183","unstructured":"Mirabegron. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development; 2020 [cited 2025 May 13]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559653\/. Accessed 13 May 2025."},{"key":"1246_CR184","unstructured":"Peacock K, Carlson K, Ketvertis KM. Menopause. StatPearls [Internet]. StatPearls Publishing; 2023 [cited 2025 Apr 23]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507826\/. Accessed 23 Apr 2025."},{"key":"1246_CR185","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/S00415-013-7131-8\/METRICS","volume":"261","author":"R Bove","year":"2014","unstructured":"Bove R, Chitnis T, Houtchens M. Menopause in multiple sclerosis: therapeutic considerations. J Neurol [Internet]. 2014;261:1257\u201368. https:\/\/doi.org\/10.1007\/S00415-013-7131-8\/METRICS.","journal-title":"J Neurol [Internet]."},{"key":"1246_CR186","doi-asserted-by":"publisher","DOI":"10.1111\/ENE.16566","volume":"32","author":"CS Simonsen","year":"2025","unstructured":"Simonsen CS, Flemmen H\u00d8, Broch L, Myklebust H, Berg-Hansen P, Brunborg C, et al. The influence of menopause on multiple sclerosis. Eur J Neurol. 2025;32:e16566. https:\/\/doi.org\/10.1111\/ENE.16566.","journal-title":"Eur J Neurol"},{"key":"1246_CR187","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/1352458520952022\/FORMAT\/EPUB","volume":"28","author":"L Midaglia","year":"2022","unstructured":"Midaglia L, Otero S, Bar\u00f3 F, Montalban X, Tintor\u00e9 M. Menopause and multiple sclerosis: influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy. Multiple Sclerosis Journal [Internet]. 2022;28:173\u201382. https:\/\/doi.org\/10.1177\/1352458520952022\/FORMAT\/EPUB.","journal-title":"Multiple Sclerosis Journal [Internet]."},{"key":"1246_CR188","unstructured":"MS minute: menopause and multiple sclerosis [Internet]. [cited 2025 May 13]. https:\/\/practicalneurology.com\/diseases-diagnoses\/ms-immune-disorders\/ms-minutebrmenopause-and-multiple-sclerosis\/32119\/. Accessed 13 May 2025."},{"key":"1246_CR189","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","volume":"401","author":"S Lederman","year":"2023","unstructured":"Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401:1091\u2013102. https:\/\/doi.org\/10.1016\/S0140-6736(23)00085-5.","journal-title":"Lancet"},{"key":"1246_CR190","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231197056","volume":"29","author":"D Morales-Rodriguez","year":"2023","unstructured":"Morales-Rodriguez D, Anderson A, Nylander A, Hsu S, Singh J, Rowles W, et al. Well-being at midlife: correlates of mental health in ambulatory menopausal women with multiple sclerosis. Mult Scler J. 2023;29:1493. https:\/\/doi.org\/10.1177\/13524585231197056.","journal-title":"Mult Scler J"},{"key":"1246_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2021.554375","author":"R Bove","year":"2021","unstructured":"Bove R, Okai A, Houtchens M, Elias-Hamp B, Lugaresi A, Hellwig K, et al. Effects of menopause in women with multiple sclerosis: an evidence-based review. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/FNEUR.2021.554375.","journal-title":"Front Neurol"},{"key":"1246_CR192","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jsxm.2017.05.018","volume":"14","author":"SA Kingsberg","year":"2017","unstructured":"Kingsberg SA, Althof S, Simon JA. Female sexual dysfunction\u2014medical and psychological treatments, committee 14. J Sex Med. 2017;14:1463\u201391. https:\/\/doi.org\/10.1016\/j.jsxm.2017.05.018.","journal-title":"J Sex Med"},{"key":"1246_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00060-7","author":"M Gulati","year":"2023","unstructured":"Gulati M, Dursun E, Vincent K, Watt FE. The influence of sex hormones on musculoskeletal pain and osteoarthritis. Lancet Rheumatol. 2023. https:\/\/doi.org\/10.1016\/S2665-9913(23)00060-7.","journal-title":"Lancet Rheumatol"},{"key":"1246_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/J.ECLINM.2023.102033","volume":"60","author":"H Liao","year":"2023","unstructured":"Liao H, Cheng J, Pan D, Deng Z, Liu Y, Jiang J, et al. Association of earlier age at menopause with risk of incident dementia, brain structural indices and the potential mediators: a prospective community-based cohort study. EClinicalMedicine. 2023;60:102033. https:\/\/doi.org\/10.1016\/J.ECLINM.2023.102033.","journal-title":"EClinicalMedicine"},{"key":"1246_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/J.MCE.2014.01.013","volume":"389","author":"EL Scott","year":"2014","unstructured":"Scott EL, Zhang Q, Vadlamudi RK, Brann DW. Premature menopause and risk of neurological disease: basic mechanisms and clinical implications. Mol Cell Endocrinol. 2014;389:2. https:\/\/doi.org\/10.1016\/J.MCE.2014.01.013.","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"1246_CR196","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1136\/JNNP-2019-320587","volume":"90","author":"D Baroncini","year":"2019","unstructured":"Baroncini D, Annovazzi PO, De Rossi N, Mallucci G, Torri Clerici V, Tonietti S, et al. Impact of natural menopause on multiple sclerosis: a multicentre study. J Neurol Neurosurg Psychiatry. 2019;90(11):1201\u20136. https:\/\/doi.org\/10.1136\/JNNP-2019-320587.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1246_CR197","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000496374","volume":"80","author":"F Ladeira","year":"2019","unstructured":"Ladeira F, Salavisa M, Caetano A, Barbosa R, S\u00e1 F, Correia AS. The influence of menopause in multiple sclerosis course: a longitudinal cohort study. Eur Neurol. 2019;80:223\u20137. https:\/\/doi.org\/10.1159\/000496374.","journal-title":"Eur Neurol"},{"key":"1246_CR198","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210228","volume":"104","author":"HE Silverman","year":"2024","unstructured":"Silverman HE, Bostrom A, Nylander AN, Akula A, Lazar AA, Gomez R, et al. Association of menopause with functional outcomes and disease biomarkers in women with multiple sclerosis. Neurology [Internet]. 2024;104:e210228. https:\/\/doi.org\/10.1212\/WNL.0000000000210228.","journal-title":"Neurology [Internet]."},{"key":"1246_CR199","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/J.MATURITAS.2020.03.001","volume":"135","author":"V Karageorgiou","year":"2020","unstructured":"Karageorgiou V, Lambrinoudaki I, Goulis DG. Menopause in women with multiple sclerosis: a systematic review. Maturitas. 2020;135:68\u201373. https:\/\/doi.org\/10.1016\/J.MATURITAS.2020.03.001.","journal-title":"Maturitas"},{"issue":"1","key":"1246_CR200","doi-asserted-by":"publisher","DOI":"10.1186\/S12883-023-03332-1","volume":"23","author":"Z Shahraki","year":"2023","unstructured":"Shahraki Z, Rastkar M, Rastkar E, Mohammadifar M, Mohamadi A, Ghajarzadeh M. Impact of menopause on relapse rate and disability level in patients with multiple sclerosis (MS): a systematic review and meta-analysis. BMC Neurol. 2023;23(1):316. https:\/\/doi.org\/10.1186\/S12883-023-03332-1.","journal-title":"BMC Neurol"},{"issue":"2","key":"1246_CR201","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/1352458512451510","volume":"19","author":"M Tutuncu","year":"2012","unstructured":"Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, et al. Onset of progressive phase is an age dependent clinical milestone in multiple sclerosis. Mult Scler. 2012;19(2):188\u201398. https:\/\/doi.org\/10.1177\/1352458512451510.","journal-title":"Mult Scler"},{"key":"1246_CR202","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANEUROL.2025.3538","author":"F Bridge","year":"2025","unstructured":"Bridge F, Sanfilippo PG, Zhu C, Skibina O, Nguyen A-L, Kalincik T, et al. Menopause impact on multiple sclerosis disability progression. JAMA Neurol [Internet]. 2025. https:\/\/doi.org\/10.1001\/JAMANEUROL.2025.3538.","journal-title":"JAMA Neurol [Internet]"},{"key":"1246_CR203","doi-asserted-by":"publisher","unstructured":"Management of menopausal symptoms. Obstetrics and Gynecology [Internet]. 2014; 123:202\u201316. https:\/\/doi.org\/10.1097\/01.AOG.0000441353.20693.78","DOI":"10.1097\/01.AOG.0000441353.20693.78"},{"issue":"4","key":"1246_CR204","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001058","volume":"126","author":"AM Kaunitz","year":"2015","unstructured":"Kaunitz AM, Manson JE. Management of menopausal symptoms. Obstet Gynecol. 2015;126(4):859. https:\/\/doi.org\/10.1097\/AOG.0000000000001058.","journal-title":"Obstet Gynecol"},{"key":"1246_CR205","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/OGX.0000000000001181","volume":"78","author":"E Rentzeperi","year":"2023","unstructured":"Rentzeperi E, Pegiou S, Tsakiridis I, Kalogiannidis I, Kourtis A, Mamopoulos A, et al. Diagnosis and management of osteoporosis: a comprehensive review of guidelines. Obstet Gynecol Surv. 2023;78:657\u201381. https:\/\/doi.org\/10.1097\/OGX.0000000000001181.","journal-title":"Obstet Gynecol Surv"},{"key":"1246_CR206","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/S40263-014-0173-3","volume":"28","author":"S Gupta","year":"2014","unstructured":"Gupta S, Ahsan I, Mahfooz N, Abdelhamid N, Ramanathan M, Weinstock-Guttman B. Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions. CNS Drugs. 2014;28:731\u201342. https:\/\/doi.org\/10.1007\/S40263-014-0173-3.","journal-title":"CNS Drugs"},{"key":"1246_CR207","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/J.MATURITAS.2023.04.271","volume":"174","author":"P Stute","year":"2023","unstructured":"Stute P, Marsden J, Salih N, Cagnacci A. Reappraising 21 years of the WHI study: putting the findings in context for clinical practice. Maturitas. 2023;174:8\u201313. https:\/\/doi.org\/10.1016\/J.MATURITAS.2023.04.271.","journal-title":"Maturitas"},{"key":"1246_CR208","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jsbmb.2013.05.010","volume":"142","author":"VW Henderson","year":"2014","unstructured":"Henderson VW. Alzheimer\u2019s disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol. 2014;142:99\u2013106. https:\/\/doi.org\/10.1016\/j.jsbmb.2013.05.010.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1246_CR209","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1212\/WNL.0000000000002980","volume":"87","author":"VW Henderson","year":"2016","unstructured":"Henderson VW, St John JA, Hodis HN, McCleary CA, Stanczyk FZ, Shoupe D, et al. Cognitive effects of estradiol after menopause. Neurology. 2016;87:699\u2013708. https:\/\/doi.org\/10.1212\/WNL.0000000000002980.","journal-title":"Neurology"},{"key":"1246_CR210","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001326","volume":"26","author":"VM Miller","year":"2019","unstructured":"Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019;26:1071. https:\/\/doi.org\/10.1097\/GME.0000000000001326.","journal-title":"Menopause"},{"issue":"1","key":"1246_CR211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S11910-023-01326-7","volume":"24","author":"S Hsu","year":"2024","unstructured":"Hsu S, Bove R. Hormonal therapies in multiple sclerosis: a review of clinical data. Curr Neurol Neurosci Rep. 2024;24(1):1\u201315. https:\/\/doi.org\/10.1007\/S11910-023-01326-7.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"1246_CR212","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(15)00322-1","volume":"15","author":"RR Voskuhl","year":"2016","unstructured":"Voskuhl RR, Wang HJ, Wu TCJ, Sicotte NL, Nakamura K, Kurth F, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(1):35\u201346. https:\/\/doi.org\/10.1016\/S1474-4422(15)00322-1.","journal-title":"Lancet Neurol"},{"key":"1246_CR213","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/J.YFRNE.2018.07.001","volume":"50","author":"MK Houtchens","year":"2018","unstructured":"Houtchens MK, Bove R. A case for gender-based approach to multiple sclerosis therapeutics. Front Neuroendocrinol [Internet]. 2018;50:123\u201334. https:\/\/doi.org\/10.1016\/J.YFRNE.2018.07.001.","journal-title":"Front Neuroendocrinol [Internet]"},{"key":"1246_CR214","doi-asserted-by":"publisher","DOI":"10.1177\/13524585251346371","author":"M Arab Bafrani","year":"2025","unstructured":"Arab Bafrani M, Rios V, Kim MJ, Balan A, Bove R. Gynecological health: a missing link in comprehensive treatment monitoring for multiple sclerosis. Mult Scler J. 2025. https:\/\/doi.org\/10.1177\/13524585251346371.","journal-title":"Mult Scler J"},{"key":"1246_CR215","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/JNNP.2008.145805","volume":"79","author":"H Tremlett","year":"2008","unstructured":"Tremlett H, Zhao Y, Joseph J, Devonshire V, Adams D, Craig D, et al. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry [Internet]. 2008;79:1368\u201374. https:\/\/doi.org\/10.1136\/JNNP.2008.145805.","journal-title":"J Neurol Neurosurg Psychiatry [Internet]."},{"key":"1246_CR216","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/JNNP-2016-313760","volume":"87","author":"I Kister","year":"2016","unstructured":"Kister I, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand\u2019Maison F, et al. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry [Internet]. 2016;87:1133\u20137. https:\/\/doi.org\/10.1136\/JNNP-2016-313760.","journal-title":"J Neurol Neurosurg Psychiatry [Internet]."},{"key":"1246_CR217","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2020.102591","author":"M Pasca","year":"2021","unstructured":"Pasca M, Forci B, Mariottini A, Mechi C, Barilaro A, Massacesi L, et al. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021. https:\/\/doi.org\/10.1016\/J.MSARD.2020.102591.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"1246_CR218","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1007\/S00415-020-10029-9","volume":"267","author":"AL Kaminsky","year":"2020","unstructured":"Kaminsky AL, Omorou AY, Soudant M, Pittion-Vouyovitch S, Michaud M, Anxionnat R, et al. Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease inactivity. J Neurol. 2020;267(12):3518\u201327. https:\/\/doi.org\/10.1007\/S00415-020-10029-9.","journal-title":"J Neurol"},{"key":"1246_CR219","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, et al. Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol. 2023;22:568\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(23)00154-0.","journal-title":"Lancet Neurol"},{"key":"1246_CR220","doi-asserted-by":"publisher","DOI":"10.3389\/FNEUR.2022.829331","author":"MC Buscarinu","year":"2022","unstructured":"Buscarinu MC, Reni\u00e8 R, Morena E, Romano C, Bellucci G, Marrone A, et al. Late-onset ms: disease course and safety-efficacy of DMTS. Front Neurol. 2022. https:\/\/doi.org\/10.3389\/FNEUR.2022.829331.","journal-title":"Front Neurol"},{"key":"1246_CR221","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208051","volume":"102","author":"EF Mouresan","year":"2024","unstructured":"Mouresan EF, Mentesidou E, Berglund A, McKay KA, Hillert J, Iacobaeus E. Clinical characteristics and long-term outcomes of late-onset multiple sclerosis: a Swedish nationwide study. Neurology. 2024;102:e208051. https:\/\/doi.org\/10.1212\/WNL.0000000000208051.","journal-title":"Neurology"},{"key":"1246_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106184","author":"A Tun\u00e7","year":"2025","unstructured":"Tun\u00e7 A, Sefero\u011flu M, Sivaci A\u00d6, K\u00f6kt\u00fcrk MD, Polat AK. Pediatric, adult, and late-onset multiple sclerosis patients: a unified analysis of clinical profiles and treatment responses. Mult Scler Relat Disord. 2025. https:\/\/doi.org\/10.1016\/j.msard.2024.106184.","journal-title":"Mult Scler Relat Disord"},{"key":"1246_CR223","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213744","author":"C Robin","year":"2025","unstructured":"Robin C, Rollot F, Lefort M, Casey R, Vukusic S, Mathey G, et al. Use of disease-modifying therapies in patients with late-onset multiple sclerosis. Neurology. 2025. https:\/\/doi.org\/10.1212\/WNL.0000000000213744.","journal-title":"Neurology"},{"key":"1246_CR224","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1474-4422(12)70056-X","volume":"11","author":"V Devonshire","year":"2012","unstructured":"Devonshire V, Havrdova E, Radue EW, O\u2019Connor P, Zhang-Auberson L, Agoropoulou C, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol [Internet]. 2012;11:420\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(12)70056-X.","journal-title":"Lancet Neurol [Internet]."},{"key":"1246_CR225","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/S00415-009-0093-1","volume":"256","author":"M Hutchinson","year":"2009","unstructured":"Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256:405\u201315. https:\/\/doi.org\/10.1007\/S00415-009-0093-1.","journal-title":"J Neurol"},{"key":"1246_CR226","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ANA.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol [Internet]. 2009;66:460\u201371. https:\/\/doi.org\/10.1002\/ANA.21867.","journal-title":"Ann Neurol [Internet]."},{"key":"1246_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106153","author":"P Faustino","year":"2024","unstructured":"Faustino P, Cruz DM, Fernandes C, Pereira A, Franco R, Costa S, et al. The role of disease modifying therapies in late-onset multiple sclerosis: a Portuguese multicentric characterization study. Mult Scler Relat Disord. 2024. https:\/\/doi.org\/10.1016\/j.msard.2024.106153.","journal-title":"Mult Scler Relat Disord"},{"key":"1246_CR228","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1111\/ENE.15006","volume":"28","author":"A Zangh\u00ec","year":"2021","unstructured":"Zangh\u00ec A, Avolio C, Amato MP, Filippi M, Trojano M, Patti F, et al. First-line therapies in late-onset multiple sclerosis: an Italian registry study. Eur J Neurol. 2021;28:4117\u201323. https:\/\/doi.org\/10.1111\/ENE.15006.","journal-title":"Eur J Neurol"},{"key":"1246_CR229","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213967","author":"S Al-Araji","year":"2025","unstructured":"Al-Araji S, Moccia M, Jha A, Zhang L, Eshaghi A, Kanber B, et al. Effectiveness of disease-modifying therapies in patients with late-onset relapsing-remitting multiple sclerosis. Neurology. 2025. https:\/\/doi.org\/10.1212\/WNL.0000000000213967.","journal-title":"Neurology"},{"key":"1246_CR230","unstructured":"Breast Cancer Statistics | How Common Is Breast Cancer? | American Cancer Society [Internet]. [cited 2025 May 14]. https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/how-common-is-breast-cancer.html. Accessed 14 May 2025."},{"key":"1246_CR231","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1177\/13524585231175975","volume":"29","author":"AN Nylander","year":"2023","unstructured":"Nylander AN, Singh J, Poole S, Anderson A, Marrie RA, Rugo H, et al. Clinical course of multiple sclerosis and patient experiences during breast cancer treatment. Mult Scler [Internet]. 2023;29:967. https:\/\/doi.org\/10.1177\/13524585231175975.","journal-title":"Mult Scler [Internet]."},{"key":"1246_CR232","doi-asserted-by":"publisher","first-page":"E1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, Craveiro L, Chognot C, Hughes R, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021;97:E1546\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000012700.","journal-title":"Neurology"},{"issue":"5","key":"1246_CR233","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ANA.25701","volume":"87","author":"P Alping","year":"2020","unstructured":"Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol. 2020;87(5):688\u201399. https:\/\/doi.org\/10.1002\/ANA.25701.","journal-title":"Ann Neurol"},{"key":"1246_CR234","doi-asserted-by":"publisher","DOI":"10.1016\/J.MSARD.2020.102627","volume":"47","author":"M Fereidan-Esfahani","year":"2021","unstructured":"Fereidan-Esfahani M, Tobin WO. Cyclophosphamide in treatment of tumefactive multiple sclerosis. Mult Scler Relat Disord. 2021;47:102627. https:\/\/doi.org\/10.1016\/J.MSARD.2020.102627.","journal-title":"Mult Scler Relat Disord"},{"key":"1246_CR235","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/1756285609344375","volume":"2","author":"A Awad","year":"2009","unstructured":"Awad A, Stue O. Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord [Internet]. 2009;2:50. https:\/\/doi.org\/10.1177\/1756285609344375.","journal-title":"Ther Adv Neurol Disord [Internet]."},{"key":"1246_CR236","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1007\/S10072-021-05052-1","volume":"42","author":"E G\u00f3mez-Figueroa","year":"2021","unstructured":"G\u00f3mez-Figueroa E, Gutierrez-Lanz E, Alvarado-Bola\u00f1os A, Casallas-Vanegas A, Garcia-Estrada C, Zabala-Angeles I, et al. Cyclophosphamide treatment in active multiple sclerosis. Neurol Sci. 2021;42:3775\u201380. https:\/\/doi.org\/10.1007\/S10072-021-05052-1.","journal-title":"Neurol Sci"},{"key":"1246_CR237","unstructured":"Breast cancer risk assessment and screening in average-risk women | ACOG [Internet]. [cited 2025 May 14]. https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-bulletin\/articles\/2017\/07\/breast-cancer-risk-assessment-and-screening-in-average-risk-women. Accessed 14 May 2025."},{"key":"1246_CR238","unstructured":"ACOG updates recommendation on when to begin breast cancer screening mammography | ACOG [Internet]. [cited 2025 May 14]. https:\/\/www.acog.org\/news\/news-releases\/2024\/10\/acog-updates-recommendation-when-to-begin-breast-cancer-screening-mammography. Accessed 14 May 2025."},{"issue":"25","key":"1246_CR239","doi-asserted-by":"publisher","first-page":"E506","DOI":"10.1161\/CIR.0000000000000912","volume":"142","author":"SR El Khoudary","year":"2020","unstructured":"El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142(25):E506\u201332. https:\/\/doi.org\/10.1161\/CIR.0000000000000912.","journal-title":"Circulation"},{"key":"1246_CR240","doi-asserted-by":"publisher","DOI":"10.3390\/JCM12062101","volume":"12","author":"M Kr\u00fcger","year":"2023","unstructured":"Kr\u00fcger M, Obst A, Ittermann T, Bernhardt O, Ivanovska T, Zygmunt M, et al. Menopause is associated with obstructive sleep apnea in a population-based sample from Mecklenburg-Western Pomerania, Germany. J Clin Med. 2023;12:2101. https:\/\/doi.org\/10.3390\/JCM12062101.","journal-title":"J Clin Med"},{"key":"1246_CR241","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2024.27154","author":"WK Nicholson","year":"2025","unstructured":"Nicholson WK, Silverstein M, Wong JB, Chelmow D, Coker TR, et al. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2025. https:\/\/doi.org\/10.1001\/JAMA.2024.27154.","journal-title":"JAMA"},{"key":"1246_CR242","doi-asserted-by":"publisher","DOI":"10.1212\/WN9.0000000000000025","author":"A Balshi","year":"2025","unstructured":"Balshi A, Jokubaitis VG, Van Der Walt A, Bove R. Cervical pathology associated with multiple sclerosis therapies. Neurol Open Access [Internet]. 2025. https:\/\/doi.org\/10.1212\/WN9.0000000000000025.","journal-title":"Neurol Open Access [Internet]"},{"key":"1246_CR243","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208059","volume":"102","author":"F Bridge","year":"2024","unstructured":"Bridge F, Brotherton J, Stankovich J, Sanfilippo PG, Skibina OG, Buzzard K, et al. Risk of cervical abnormalities for women with multiple sclerosis treated with moderate-efficacy and high-efficacy disease-modifying therapies. Neurology. 2024;102:e208059. https:\/\/doi.org\/10.1212\/WNL.0000000000208059.","journal-title":"Neurology"},{"key":"1246_CR244","doi-asserted-by":"publisher","first-page":"1119660","DOI":"10.3389\/FNEUR.2023.1119660\/FULL","volume":"14","author":"F Bridge","year":"2023","unstructured":"Bridge F, Brotherton JML, Foong Y, Butzkueven H, Jokubaitis VG, Van der Walt A. Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies. Front Neurol [Internet]. 2023;14:1119660. https:\/\/doi.org\/10.3389\/FNEUR.2023.1119660\/FULL.","journal-title":"Front Neurol [Internet]"},{"issue":"2","key":"1246_CR245","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000866","volume":"29","author":"A-B Moscicki","year":"2025","unstructured":"Moscicki A-B, Flowers L, Huchko MJ, Long ME, MacLaughlin KL, Murphy J, et al. Updated review for guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 2025;29(2):168. https:\/\/doi.org\/10.1097\/LGT.0000000000000866.","journal-title":"J Low Genit Tract Dis"},{"key":"1246_CR246","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213907","volume":"105","author":"A Gavoille","year":"2025","unstructured":"Gavoille A, Leray E, Marignier R, Rollot F, Casey R, Mathey G, et al. Sex-related gap in the use of disease-modifying therapies in multiple sclerosis. Neurology [Internet]. 2025;105:e213907. https:\/\/doi.org\/10.1212\/WNL.0000000000213907.","journal-title":"Neurology [Internet]"},{"key":"1246_CR247","unstructured":"Human Papillomavirus (HPV) Infection - STI Treatment Guidelines [Internet]. [cited 2025 Jun 18]. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/hpv-cancer.htm. Accessed 18 Jun 2025."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01246-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01246-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:09:22Z","timestamp":1771430962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01246-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":247,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1246"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01246-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Riley Bove has received research support from Alexion, Biogen, EMD Serono, Novartis, Roche\/Genentech, Sanofi Genzyme, and TG Therapeutics. Riley Bove has served on advisory boards and\/or steering committees for Alexion, Biogen, EMD Serono, Novartis, Roche\/Genentech, Sanofi Genzyme, and TG Therapeutics. Kylie McConville has no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Kylie McConville\u2014idea origination, literature review and analysis, manuscript drafting and editing. Riley Bove\u2014idea origination, literature review and analysis, manuscript drafting and revision. Both authors have read and approved the final submitted manuscript and agree to be held accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s Contributions"}}]}}